{"id":"debio-4126","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug targets mitochondrial NADH dehydrogenase (complex I), impairing ATP production and inducing metabolic stress in tumor cells. This mechanism is particularly relevant in cancers with high metabolic demands or specific mitochondrial dependencies. The selective targeting aims to exploit metabolic vulnerabilities in cancer while minimizing effects on normal tissues.","oneSentence":"Debio 4126 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:42.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":"Acromegaly, GEP-NET","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Debio 4126","genericName":"Debio 4126","companyName":"Debiopharm International SA","companyId":"debiopharm-international-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Debio 4126 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}